CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Velpatasvir

维帕他韦 杂质对照品Velpatasvir Impurities

32 个杂质条目32 impurity entries

本页汇总 维帕他韦 的 32 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 32 impurity reference standards of Velpatasvir. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 维帕他韦(Velpatasvir)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesForced Degradation Studies and Development and Validation of HPLC-UV Method for the Analysis of Velpatasvir Copovidone Solid Dispersion
    Antibiotics (Basel, Switzerland) · 2022 · Zaman B et al.  ·  PMID 35884151  ·  DOI
  2. 杂质研究Impurity studiesStudy on fluorescence properties of HCV antiviral (velpatasvir) and its fluorimetric determination in presence of sofosbuvir; application to stability study and human plasma
    Luminescence : the journal of biological and chemical luminescence · 2018 · Omar MA et al.  ·  PMID 30144265  ·  DOI
  3. 分析方法Analytical MethodsDevelopment and validation of a stability-Indicating RP-HPLC method for simultaneous estimation of sofosbuvir and velpatasvir in fixed dose combination tablets and plasma
    Pakistan journal of pharmaceutical sciences · 2019 · Mehmood Y et al.  ·  PMID 31680080
  4. 分析方法Analytical MethodsTwo novel UPLC methods utilizing two different analytical columns and different detection approaches for the simultaneous analysis of velpatasvir and sofosbuvir: application to their co-formulated tablet
    BMC chemistry · 2019 · Moustapha ME et al.  ·  PMID 31583391  ·  DOI
  5. 分析方法Analytical MethodsRapid bioanalytical LC-MS/MS method for the simultaneous determination of sofosbuvir and velpatasvir in human plasma-application to a pharmacokinetic study in Egyptian volunteers
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2018 · Elkady EF, Aboelwafa AA  ·  PMID 30384188  ·  DOI

维帕他韦 —— 原料药与杂质对照品Velpatasvir — drug substance & impurities

共 33 个条目(含原料药本体)33 items incl. the drug substance
Velpatasvir structure
原料药 APIAPI
维帕他韦Velpatasvir
Velpatasvir
CAS No.1377049-84-7
Chemical FormulaC49H54N8O8
Purity>95%询价On request
10mg25mg50mg100mg
(2S,5S)-1-tert-Butyl 2-ethyl 5-methylpyrrolidine-1,2-dicarboxylate structure
—
(2S,5S)-1-叔丁基-2-乙基-5-甲基吡咯烷-1,2-二甲酸酯(2S,5S)-1-tert-Butyl 2-ethyl 5-methylpyrrolidine-1,2-dicarboxylate
(2S,5S)-1-tert-Butyl 2-ethyl 5-methylpyrrolidine-1,2-dicarboxylate
CAS No.676560-83-1
Chemical FormulaC13H23NO4
Purity>95%现货In stock
10mg25mg50mg100mg
Velpatasvir Impurity 4 structure
4
维帕他韦杂质4Velpatasvir Impurity 4
Velpatasvir Impurity 4
CAS No.1378391-45-7
Chemical FormulaC44H53N7O7
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 5 structure
5
维帕他韦杂质5Velpatasvir Impurity 5
Velpatasvir Impurity 5
CAS No.1378388-16-9
Chemical FormulaC12H21NO5
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 6 structure
6
维帕他韦杂质6Velpatasvir Impurity 6
Velpatasvir Impurity 6
CAS No.1335316-40-9
Chemical FormulaC13H22N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 7 structure
7
维帕他韦杂质7Velpatasvir Impurity 7
Velpatasvir Impurity 7
CAS No.1438383-89-1
Chemical FormulaC19H14Br2O3
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 8 structure
8
维帕他韦杂质8Velpatasvir Impurity 8
Velpatasvir Impurity 8
CAS No.1493768-22-1
Chemical FormulaC49H54N8O8
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 9 structure
9
维帕他韦杂质9Velpatasvir Impurity 9
Velpatasvir Impurity 9
CAS No.1378391-50-4
Chemical FormulaC43H52N6O7
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 10 structure
10
维帕他韦杂质10Velpatasvir Impurity 10
Velpatasvir Impurity 10
CAS No.1844064-96-5
Chemical FormulaC39H45N7O5
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 16 structure
16
维帕他韦杂质16Velpatasvir Impurity 16
Velpatasvir Impurity 16
CAS No.1493769-28-0
Chemical FormulaC53H54N8O9
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 20 structure
20
维帕他韦杂质20Velpatasvir Impurity 20
Velpatasvir Impurity 20
CAS No.946525-30-0
Chemical FormulaC7H6BrIO
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 21 structure
21
维帕他韦杂质21Velpatasvir Impurity 21
Velpatasvir Impurity 21
CAS No.1844064-89-6
Chemical FormulaC9H9BrO2
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 22 structure
22
维帕他韦杂质22Velpatasvir Impurity 22
Velpatasvir Impurity 22
CAS No.1844064-91-0
Chemical FormulaC9H8Br2O
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 23 structure
23
维帕他韦杂质23Velpatasvir Impurity 23
Velpatasvir Impurity 23
CAS No.1844064-94-3
Chemical FormulaC19H17BrO3
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 24 structure
24
维帕他韦杂质24Velpatasvir Impurity 24
Velpatasvir Impurity 24
CAS No.1438383-92-6
Chemical FormulaC19H16O3
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 25 structure
25
维帕他韦杂质25Velpatasvir Impurity 25
Velpatasvir Impurity 25
CAS No.1378391-42-4
Chemical FormulaC31H34BrNO8
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 26 structure
26
维帕他韦杂质26Velpatasvir Impurity 26
Velpatasvir Impurity 26
CAS No.2377748-85-9
Chemical FormulaC44H55N5O10
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 27 structure
27
维帕他韦杂质27Velpatasvir Impurity 27
Velpatasvir Impurity 27
CAS No.1378391-44-6
Chemical FormulaC44H55N7O7
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 28 structure
28
维帕他韦杂质28Velpatasvir Impurity 28
Velpatasvir Impurity 28
CAS No.50890-96-5
Chemical FormulaC10H11NO4
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 29 structure
29
维帕他韦杂质29Velpatasvir Impurity 29
Velpatasvir Impurity 29
CAS No.24277-38-1
Chemical FormulaC15H27NO6
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 30 structure
30
维帕他韦杂质30Velpatasvir Impurity 30
Velpatasvir Impurity 30
CAS No.2258-42-6
Chemical FormulaC3H4O3
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 31 structure
31
维帕他韦杂质31Velpatasvir Impurity 31
Velpatasvir Impurity 31
CAS No.1643468-78-3
Chemical FormulaC16H25NO6
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 32 structure
32
维帕他韦杂质32Velpatasvir Impurity 32
Velpatasvir Impurity 32
CAS No.1844064-30-7
Chemical FormulaC16H27NO6
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 33 structure
33
维帕他韦杂质33Velpatasvir Impurity 33
Velpatasvir Impurity 33
CAS No.1313208-11-5
Chemical FormulaC15H27NO5
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 34 structure
34
维帕他韦杂质34Velpatasvir Impurity 34
Velpatasvir Impurity 34
CAS No.1313208-13-7
Chemical FormulaC11H19NO5
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 35 structure
35
维帕他韦杂质35Velpatasvir Impurity 35
Velpatasvir Impurity 35
CAS No.1378389-12-8
Chemical FormulaC12H21NO5
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 36 structure
36
维帕他韦杂质36Velpatasvir Impurity 36
Velpatasvir Impurity 36
CAS No.2167945-77-7
Chemical FormulaC12H21NO5
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 37 structure
37
维帕他韦杂质37Velpatasvir Impurity 37
Velpatasvir Impurity 37
CAS No.144978-12-1
Chemical FormulaC12H19NO5
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 38 structure
38
维帕他韦杂质38Velpatasvir Impurity 38
Velpatasvir Impurity 38
CAS No.913251-58-8
Chemical FormulaC13H23NO5
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 40 structure
40
维帕他韦杂质40Velpatasvir Impurity 40
Velpatasvir Impurity 40
CAS No.676560-84-2
Chemical FormulaC8H15NO2
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 41 structure
41
维帕他韦杂质41Velpatasvir Impurity 41
Velpatasvir Impurity 41
CAS No.1335316-39-6
Chemical FormulaC15H26N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 42 structure
42
维帕他韦杂质42Velpatasvir Impurity 42
Velpatasvir Impurity 42
CAS No.2226161-34-6
Chemical FormulaC14H24N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Velpatasvir Impurity 43 structure
43
维帕他韦杂质43Velpatasvir Impurity 43
Velpatasvir Impurity 43
CAS No.1377049-43-8
Chemical FormulaC45H54N8O7
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

维帕他韦 —— 研究文献与合成路线Velpatasvir — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 维帕他韦 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Velpatasvir. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Forced Degradation Studies and Development and Validation of HPLC-UV Method for the Analysis of Velpatasvir Copovidone Solid Dispersion
    Zaman B, Hassan W, Khan A, et al. · Antibiotics (Basel, Switzerland) · 2022 · 被引 2cited 2
  2. A Box-Behnken design optimization based ecofriendly RP-HPLC method For Estimation of sofosbuvir And velpatasvir - Application to stability indicating assay
    Bairam R, Tatapudi HK, Gajji N, et al. · 2023
  3. Selective and sensitive spectrofluorimetric quantification of velpatasvir in presence of sofosbuvir. Application to their co-formulated tablet
    El-Gamal RM, Abdel-Gawad SA, Belal FF, et al. · RSC advances · 2018 · 被引 5cited 5

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

维帕他韦 杂质谱研究要点Velpatasvir — impurity profiling notes

下面这些是拿到 维帕他韦 的 33 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 33 impurity entries for Velpatasvir, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances